Skip to content

Research at St Andrews

The importance of clinical pharmacokinetic–pharmacodynamic studies in unraveling the determinants of early and late tuberculosis outcomes

Research output: Contribution to journalReview article


Open Access permissions



Andrew D McCallum, Derek James Sloan

School/Research organisations


Tuberculosis remains a major infectious cause of morbidity and mortality worldwide. Current antibiotic regimens, constructed prior to the development of modern pharmacokinetic-pharmacodynamic (PK–PD) tools, are based on incomplete understanding of exposure–response relationships in drug susceptible and multidrug resistant tuberculosis. Preclinical and population PK data suggest that clinical PK–PD studies may enable therapeutic drug monitoring for some agents and revised dosingf or others. Future clinical PK–PD challenges include: incorporation of PK methods to assay free concentrations for all active metabolites; selection of appropriate early outcome measures which reflect therapeutic response; elucidation of genetic contributors to interindividual PK variability; conduct of targeted studies on special populations (including children); and measurement of PK–PD parameters at the site of disease.


Original languageEnglish
Pages (from-to)195-212
JournalInternational Journal of Pharmacokinetics
Issue number3
Early online date12 Jul 2017
Publication statusPublished - Jul 2017

    Research areas

  • Clinical trials, Compartmental pharmacokinetics, Multidrug-resistant tuberculosis, Pharmacogenetics, Pharmacokinetics-pharmacodynamics, Therapeutic drug monitoring, Tuberculosis

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. A tuberculosis molecular bacterial load assay (TB-MBLA)

    Sabiiti, W., Mtafya, B. A., Alferes De Lima, D., Dombay, E., Baron, V. O., Azam, K., Orascova, K., Sloan, D. J. & Gillespie, S. H., 6 Sep 2019, (Accepted/In press) In : Journal of Visualized Experiments.

    Research output: Contribution to journalArticle

  2. Protocol for the development of the STrengthening the Reporting of Pharmacogenetic Studies (STROPS) guideline: checklist of items for reporting pharmacogenetic studies

    Richardson, M., Kirkham, J. J., Dwan, K. M., Sloan, D. J., Davies, G. & Jorgensen, A., 11 Jul 2019, In : BMJ Open. 9, 7, 5 p., e030212.

    Research output: Contribution to journalArticle

  3. Linezolid for drug-resistant pulmonary tuberculosis

    Singh, B., Cocker, D., Ryan, H. & Sloan, D. J., 20 Mar 2019, In : Cochrane Database of Systematic Reviews. 2019, 3, CD012836.

    Research output: Contribution to journalReview article

  4. Evaluation of the efficacy of two methods for direct extraction of DNA from Mycobacterium tuberculosis sputum

    Ndhlovu, V., Mandala, W., Sloan, D., Kamdolozi, M., Caws, M. & Davies, G., 31 Dec 2018, In : Journal of Infection in Developing Countries. 12, 12, p. 1067-1072 6 p.

    Research output: Contribution to journalArticle

  5. Effect of the duration of antimicrobial exposure on the development of antimicrobial resistance (AMR) for macrolide antibiotics: protocol for a systematic review with a network meta-analysis

    Divala, T. H., Corbett, E. L., Stagg, H. R., Nliwasa, M., Sloan, D. J., French, N. & Fielding, K. L., 23 Dec 2018, In : Systematic Reviews. 7, 9 p., 246.

    Research output: Contribution to journalArticle

ID: 251504347